Published in Cancer Res on May 15, 2005
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck | NCT04150900
Clearance of apoptotic cells: implications in health and disease. J Cell Biol (2010) 3.55
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 2.66
CNS delivery via adsorptive transcytosis. AAPS J (2008) 1.46
Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis (2010) 1.42
Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. J Am Chem Soc (2010) 1.34
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res (2008) 1.23
Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem (2012) 1.10
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ (2016) 1.01
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia (2012) 0.96
High resolution tumor targeting in living mice by means of multispectral optoacoustic tomography. EJNMMI Res (2012) 0.95
Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. Transl Oncol (2011) 0.88
Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine. PLoS One (2013) 0.86
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat (2010) 0.86
Exposure of phosphatidylserine on the cell surface. Cell Death Differ (2016) 0.86
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. J Biomed Sci (2014) 0.84
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids. Invest New Drugs (2015) 0.81
Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther (2010) 0.81
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res (2016) 0.81
The phospholipid code: a key component of dying cell recognition, tumor progression and host-microbe interactions. Cell Death Differ (2015) 0.80
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med (2015) 0.79
The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol (2005) 0.79
Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol (2016) 0.79
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. Am J Nucl Med Mol Imaging (2015) 0.78
Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. Invest Ophthalmol Vis Sci (2015) 0.77
Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. Oncotarget (2016) 0.77
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77
A combination of radiosurgery and soluble tissue factor enhances vascular targeting for experimental glioblastoma. Biomed Res Int (2013) 0.77
Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions. J Immunol Res (2015) 0.76
Measuring response to therapy by near-infrared imaging of tumors using a phosphatidylserine-targeting antibody fragment. Mol Imaging (2013) 0.76
Detection of cancer cells using SapC-DOPS nanovesicles. Mol Cancer (2016) 0.75
Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget (2016) 0.75
Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes. Chem Commun (Camb) (2016) 0.75
Identification of the minimum pharmacophore of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1D1. Bioorg Med Chem (2016) 0.75
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res (2002) 2.21
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest (2010) 1.77
Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med (2008) 1.64
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys (2002) 1.62
Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res (2005) 1.50
Refrigerator blindness: selective loss of visual acuity in association with a common foraging behaviour. CMAJ (2005) 1.38
A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis (2002) 1.37
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res (2008) 1.23
Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res (2009) 1.17
Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res (2007) 1.16
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res (2013) 1.13
Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. Neoplasia (2011) 1.10
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate (2004) 1.07
Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem (2006) 1.05
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med (2010) 1.02
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 1.00
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia (2003) 1.00
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia (2005) 1.00
Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer (2006) 0.99
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia (2005) 0.99
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia (2012) 0.96
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy (2011) 0.92
Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochim Biophys Acta (2008) 0.91
Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. Transl Oncol (2011) 0.88
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat (2010) 0.86
Correlation of probiotic Lactobacillus salivarius growth phase with its cell wall-associated proteome. FEMS Microbiol Lett (2005) 0.86
An open trial in the NHS of Blues Begone: a new home based computerized CBT program. Behav Cogn Psychother (2009) 0.84
Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4. Cell Cycle (2009) 0.84
Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. J Cell Biochem Suppl (2002) 0.83
Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. J Biomed Nanotechnol (2014) 0.82
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res (2006) 0.82
Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine (2011) 0.81
Routine, empathic and compassionate patient care: definitions, development, obstacles, education and beneficiaries. J Eval Clin Pract (2014) 0.80
Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer (2011) 0.80
Iatrogenic hyponatremia in hospitalized children: Can it be avoided? Paediatr Child Health (2008) 0.79
Phosphatidylserine externalization and membrane blebbing are involved in the nonclassical export of FGF1. J Cell Biochem (2012) 0.79
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. Biochem Pharmacol (2012) 0.76
The SYNCAN project: goals, set-up, first results and settings of the human intervention study. Br J Nutr (2005) 0.75
Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. Anticancer Res (2011) 0.75
Immune function and health outcomes in women with depression. Biopsychosoc Med (2010) 0.75
Canadian Guidelines for Controlled Pediatric Donation After Circulatory Determination of Death-Summary Report. Pediatr Crit Care Med (2017) 0.75
Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. Adv Exp Med Biol (2003) 0.75